For how we live.
Every article we have published on Mosquito Borne Disease, newest first.
Trials show both new vaccines raise protective antibody levels in almost everyone. The unsettled question is the live-attenuated shot's safety in the older adults most likely to be hospitalised.
A single infusion of a pan-serotype monoclonal antibody cut viraemia and shortened fever in a 250-patient phase 2 trial in India — the first therapy to show preliminary efficacy against wild-type dengue in people.
Across 166,390 tests during Brazil's outbreak, two TAK-003 doses were 73% effective against symptomatic dengue and 88% against hospitalisation, with no sign of waning.
Italy logged 296 locally acquired cases in 2024, a European record. Transmission rose 19.8% per 1°C of warming, and modelling puts most of France in range for the mosquito that carries it this century.
429 cases across nine countries, and a mosquito species that transmits two other viruses now established in 16 European countries — double the number from twelve years ago.
More than 410,000 probable cases so far in 2026, against 1.45 million for all of 2025. One state, Minas Gerais, accounts for roughly a sixth of the national case total on its own.
A cluster-randomised trial in Cúcuta coated water containers in 13,803 homes. Dengue incidence fell to 337 per 100,000 versus 528 in control clusters, at about US$2 per household a year.
Four years after the virus was first detected in south-eastern Australia, interviews in Tamworth find eligibility for a free vaccine has not translated into uptake.
In a 20,000-child trial across eight endemic countries, TAK-003 was 61.2% effective against symptomatic dengue and 84.1% against hospitalisation — but protection was narrower in children never previously infected.